Research progress on biomarkers of left atrial thrombus in atrial fibrillation

HE Yuanqiang; GAO Wenjun; XU Zhaoyuan; WU Yingjie; JIN Haiyan; ZHANG Le

doi:10.7619/jcmp.20211764

Journal of Clinical Medicine in Practice > 2021 > 25(19): 128-132. > DOI: 10.7619/jcmp.20211764

HE Yuanqiang, GAO Wenjun, XU Zhaoyuan, WU Yingjie, JIN Haiyan, ZHANG Le. Research progress on biomarkers of left atrial thrombus in atrial fibrillation[J]. Journal of Clinical Medicine in Practice, 2021, 25(19): 128-132. DOI: 10.7619/jcmp.20211764

Citation:

PDF (599 KB)

Research progress on biomarkers of left atrial thrombus in atrial fibrillation

Department of Cardiology, the Third People's Hospital of Kunming City in Yunnan Province, Kunming, Yunnan, 650041

More Information

Received Date: April 25, 2021
Available Online: October 27, 2021
Published Date: October 14, 2021

Graphical Abstract

Abstract

Abstract

Left atrial thromboembolism seriously affects the quality of life of patients with atrial fibrillation, and even threatens their life safety. Recent studies have shown that biomarkers of left atrial thrombosis for atrial fibrillation can be used for early risk assessment in high-risk groups, and are important references for studying pathophysiological and mechanism of left atrial thrombosis in atrial fibrillation, as well as important indicators for measuring novel treatment methods. This article reviewed the application prospect of the biomarker system left atrial thrombosis for in atrial fibrillation in clinical practice and related clinical research progress.
- atrial fibrillation,
- thrombosis,
- left atrial,
- biomarkers

FullText(HTML)

References (37)

References

[1]	马春鸽, 王现青, 姚焰. 左心耳形态结构和功能与心房颤动相关性卒中的研究和展望[J]. 中国心血管病研究, 2021, 19(3): 260-264. doi: 10.3969/j.issn.1672-5301.2021.03.014
[2]	KORNEJ J, APOSTOLAKIS S, BOLLMANN A, et al. The emerging role of biomarkers in atrial fibrillation[J]. Can J Cardiol, 2013, 29(10): 1181-1193. doi: 10.1016/j.cjca.2013.04.016
[3]	LIU T, LI L J, KORANTZOPOULOS P, et al. Meta-analysis of association between C-reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation[J]. Am J Cardiol, 2008, 101(12): 1749-1752. doi: 10.1016/j.amjcard.2008.02.066
[4]	HIJAZI Z, OLDGREN J, SIEGBAHN A, et al. Biomarkers in atrial fibrillation: a clinical review[J]. Eur Heart J, 2013, 34(20): 1475-1480. doi: 10.1093/eurheartj/eht024
[5]	WEITZ J I, FREDENBURGH J C, EIKELBOOM J W. A test in context: D-dimer[J]. J Am Coll Cardiol, 2017, 70(19): 2411-2420. doi: 10.1016/j.jacc.2017.09.024
[6]	HAAPANIEMI E, TATLISUMAK T. Is D-dimer helpful in evaluating stroke patients A systematic review[J]. Acta Neurol Scand, 2009, 119(3): 141-150. doi: 10.1111/j.1600-0404.2008.01081.x
[7]	DANESE E, MONTAGNANA M, CERVELLIN G, et al. Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence[J]. Ann Med, 2014, 46(6): 364-371. doi: 10.3109/07853890.2014.912835
[8]	LIPPI G, FRANCHINI M, TARGHER G, et al. Help me, Doctor!My D-dimer is raised[J]. Ann Med, 2008, 40(8): 594-605. doi: 10.1080/07853890802161015
[9]	CHRISTERSSON C, WALLENTIN L, ANDERSSON U, et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation: observations from the ARISTOTLE trial[J]. J Thromb Haemost, 2014, 12(9): 1401-1412. doi: 10.1111/jth.12638
[10]	SADANAGA T, SADANAGA M, OGAWA S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy[J]. J Am Coll Cardiol, 2010, 55(20): 2225-2231. doi: 10.1016/j.jacc.2009.12.049
[11]	SADANAGA T, KOHSAKA S, OGAWA S. D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy[J]. Cardiology, 2010, 117(1): 31-36. doi: 10.1159/000319626
[12]	HABARA S, DOTE K, KATO M, et al. Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation[J]. Eur Heart J, 2007, 28(18): 2217-2222. doi: 10.1093/eurheartj/ehm356
[13]	SOMLÓI M, TOMCSÁNYI J, NAGY E, et al. D-dimer determination as a screening tool to exclude atrial thrombi in atrial fibrillation[J]. Am J Cardiol, 2003, 92(1): 85-87. doi: 10.1016/S0002-9149(03)00476-4
[14]	BODY R, ALLIE B. Negative D-dimer may allow safe early cardioversion of atrial fibrillation[J]. Emerg Med J, 2007, 24(6): 432-435. doi: 10.1136/emj.2007.049510
[15]	MAHÉ I, BERGMANN J F, CHASSANY O, et al. A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fibrillation[J]. Thromb Res, 2012, 129(6): 693-699. doi: 10.1016/j.thromres.2011.08.014
[16]	ROLDÁN V, MARÍN F, MUIÑA B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients[J]. J Am Coll Cardiol, 2011, 57(25): 2496-2504. doi: 10.1016/j.jacc.2010.12.033
[17]	KRARUP L H, SANDSET E C, SANDSET P M, et al. D-dimer levels and stroke progression in patients with acute ischemic stroke and atrial fibrillation[J]. Acta Neurol Scand, 2011, 124(1): 40-44. doi: 10.1111/j.1600-0404.2010.01409.x
[18]	LIP G Y, LOWE G D, RUMLEY A, et al. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment[J]. Br Heart J, 1995, 73(6): 527-533. doi: 10.1136/hrt.73.6.527
[19]	LI-SAW-HEE F L, BLANN A D, GURNEY D, et al. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function[J]. Eur Heart J, 2001, 22(18): 1741-1747. doi: 10.1053/euhj.2000.2531
[20]	LIP G Y, LOWE G D, RUMLEY A, et al. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis[J]. Am Heart J, 1996, 131(4): 724-730. doi: 10.1016/S0002-8703(96)90278-1
[21]	CHOUDHURY A, CHUNG I, BLANN A, et al. Platelet adhesion in atrial fibrillation[J]. Thromb Res, 2007, 120(4): 623-629. doi: 10.1016/j.thromres.2006.12.008
[22]	KAMATH S, CHIN B S, BLANN A D, et al. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation[J]. Blood Coagul Fibrinolysis, 2002, 13(7): 627-636. doi: 10.1097/00001721-200210000-00008
[23]	MURUGESAN V, PULIMAMIDI V K, RAJAPPA M, et al. Elevated fibrinogen and lowered homocysteine-vitamin determinants and their association with left atrial Thrombus in patients with rheumatic mitral Stenosis[J]. Br J Biomed Sci, 2015, 72(3): 102-106. doi: 10.1080/09674845.2015.11666804
[24]	KELL D B, PRETORIUS E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen)[J]. Integrative Biology Quantitative Bioences from Nano to Macro, 2015, 7(1): 24. doi: 10.1039/c4ib00173g
[25]	YAO Y, SHANG M S, GAO L J, et al. Elevated homocysteine increases the risk of left atrial/left atrial appendage Thrombus in non-valvular atrial fibrillation with low CHA2DS2-VASc score[J]. Europace, 2018, 20(7): 1093-1098. doi: 10.1093/europace/eux189
[26]	AY H, ARSAVA E M, TOKGÖZOGLU S L, et al. Hyperhomocysteinemia is associated with the presence of left atrial Thrombus in stroke patients with nonvalvular atrial fibrillation[J]. Stroke, 2003, 34(4): 909-912. doi: 10.1161/01.STR.0000060202.63475.BA
[27]	OCHIUMI Y, KAGAWA E, KATO M, et al. Usefulness of brain natriuretic peptide for predicting left atrial appendage Thrombus in patients with unanticoagulated nonvalvular persistent atrial fibrillation[J]. J Arrhythm, 2015, 31(5): 307-312. doi: 10.1016/j.joa.2015.04.002
[28]	DOUKKY R, GAGE H, NAGARAJAN V, et al. B-type natriuretic peptide predicts left atrial appendage Thrombus in patients with nonvalvular atrial fibrillation[J]. Echocardiography, 2013, 30(8): 889-895. doi: 10.1111/echo.12169
[29]	SADANAGA T, MITAMURA H, FUKUDA K, et al. D-dimer levels positively correlate with B-type natriuretic peptide levels in patients with atrial fibrillation[J]. Int J Cardiol, 2012, 158(1): 110-111. doi: 10.1016/j.ijcard.2012.04.079
[30]	盛源, 郑冰清, 蔡泠, 等. 心房颤动并发血栓栓塞患者脑钠肽与D-二聚体的表达及相关性分析[J]. 现代生物医学进展, 2015, 15(7): 1271-1274, 1285. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201507019.htm
[31]	王增夏, 王贺, 邱承杰, 等. 心房颤动发病机制的研究进展[J]. 中国医药导报, 2018, 15(15): 26-29. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201815007.htm
[32]	BAYKANER T, ROGERS A J, MECKLER G L, et al. Clinical implications of ablation of drivers for atrial fibrillation: a systematic review and meta-analysis[J]. Circ Arrhythm Electrophysiol, 2018, 11(5): e006119.
[33]	TEUNISSEN C, CLAPPERS N, HASSINK R J, et al. A decade of atrial fibrillation ablation[J]. Neth Heart J, 2017, 25(10): 559-566. doi: 10.1007/s12471-017-1019-7
[34]	胡小菁. 心房颤动的相关因素研究[D]. 西安: 第四军医大学, 2007.
[35]	王艳. 房颤介入治疗前经食管超声心动图对左心房及左心房耳血栓检出的临床意义[J]. 现代医用影像学, 2016, 25(5): 987-988. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYY201605066.htm
[36]	PASSMAN R. Atrial fibrillation and stroke: The more we learn, the less we understand[J]. Am Heart J, 2018, 201: 158-159. doi: 10.1016/j.ahj.2018.04.009
[37]	Shirani, J., Alaeddini, J. Structural remodeling of the left atrial appendage in patients with chronic non-valvular atrial fibrillation: implications for thrombus formation, systemic embolism, and assessment by transesophageal echocardiography[J]. Cardiovascular Pathology, 2000, 9(2): 95-101. doi: 10.1016/S1054-8807(00)00030-2

Cited By

Get Citation

PDF

XML

Article views (291) PDF downloads (14)

Turn off MathJax

Article Contents

Abstract

References

Research progress on biomarkers of left atrial thrombus in atrial fibrillation

Abstract

References

Catalog

Export File

Citation

Format

Content